Research programme: fibrotic liver diseases therapeutics - Boehringer Ingelheim/MiNA Therapeutics

Drug Profile

Research programme: fibrotic liver diseases therapeutics - Boehringer Ingelheim/MiNA Therapeutics

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; MiNA Therapeutics
  • Class
  • Mechanism of Action RNA interference; RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Nov 2017 MiNA Therapeutics has patent protection for saRNA technology platform in USA granted before November 2017 (MiNA Therapeutics pipeline, November 2017)
  • 09 Nov 2017 Boehringer Ingelheim and MiNA Therapeutics enter into a collaboration agreement to develop fibrotic liver diseases therapeutics
  • 09 Nov 2017 Early research in Non-alcoholic steatohepatitis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top